TABLE IX.
Bone-Defect Healing in the Intention-to-Treat Population (N = 133) According to the Jerosch Score*
| Visit and Stage of Remodeling | Autologous Iliac Bone-Graft Group† (N = 68) | CBVF Group† (N = 65) | Total† (N = 133) | P Value‡ |
| Visit 5: week 6 | 0.6612 | |||
| R0 (no bone remodeling visible) | 1 (1.8%) | 3 (5.9%) | 4 (3.8%) | |
| R1 (beginning bone remodeling with periosteal bridging) | 27 (50.0%) | 24 (47.1%) | 51 (48.6%) | |
| R2 (bone remodeling with nondirectional trabecular structure) | 21 (38.9%) | 21 (41.2%) | 42 (40.0%) | |
| R3 (complete bone remodeling with directional trabecular structure) | 5 (9.3%) | 3 (5.9%) | 8 (7.6%) | |
| Missing | 14 | 14 | 28 | |
| Visit 7: week 26 | 0.2306 | |||
| R1 (beginning bone remodeling with periosteal bridging) | 9 (18.0%) | 5 (10.4%) | 14 (14.3%) | |
| R2 (bone remodeling with nondirectional trabecular structure) | 26 (52.0%) | 33 (68.7%) | 59 (60.2%) | |
| R3 (complete bone remodeling with directional trabecular structure) | 15 (30.0%) | 10 (20.8%) | 25 (25.5%) | |
| Missing | 18 | 17 | 35 |
*
The Jerosch score assesses osteolysis, premature resorption of the graft (1 point), unchanged size of the void, no resorption of the bone graft (2 points), beginning marginal bone-defect remodeling (3 points), bone-defect remodeling with nondirectional formation of trabeculae (4 points), and bone-defect remodeling with directional formation of trabeculae (5 points).
†
The values are given as the number of patients, with or without the percentage in parentheses.
‡
Chi-square test.